Dostarlimab plus niraparib for advanced penile cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 study tests whether combining dostarlimab (an immunotherapy) with niraparib (a cancer pill) can shrink advanced penile cancer and keep it from growing. It may help people whose cancer has progressed after limited prior treatments, and who have not had certain immune therapies before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III (unresectable) or stage IV penile cancer that doctors confirmed with a tissue test.
- Your cancer must have measurable disease on scans (doctors can measure it).
- You should be able to do normal activities with limited help (ECOG 0–1, sometimes 2 by special approval).
- You have not had more than one prior treatment line in the locally advanced setting or after platinum chemotherapy.
- You cannot have used prior immune checkpoint treatments (like anti–PD-1/PD-L1/CTLA-4), cancer vaccines, or similar immune-targeting therapies.
- You must be well enough for treatment: adequate organ test results and prior chemo side effects are mostly resolved (except hair loss and mild nerve symptoms).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
This trial tests a new drug called dostarlimab, given with standard chemotherapy, for people with advanced or recurrent endometrial cancer. It aims to see if this combination can help shrink tumors or slow their growth.
This trial tests whether giving a drug called dostarlimab (an immunotherapy that boosts your immune system to fight cancer) before and after surgery can help treat advanced endometrial cancer. It is for people with stage 3 or 4 endometrial cancer who haven't had treatment yet and may be eligible if their tumor has a specific marker called mismatch repair deficiency.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
This trial studies whether the medicines niraparib and dostarlimab can slow advanced cancers that have active, growing brain metastases. It is meant for people whose brain tumors can be measured on MRI and who have had at least one previous treatment.
This trial tests whether giving the drug dostarlimab before surgery can shrink or control endometrial cancer. It is for people whose tumors have a specific genetic feature (MMR deficiency) that may make the drug more effective.
Hear when a new Penile Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.